Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

An Eli Lilly & Co. Alzheimer’s drug won Food and Drug Administration approval Tuesday, capping the medication’s bumpy ride through the U.S. regulatory process and adding a second new treatment ...

Eli Lilly (NYSE: LLY) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA). The new drug, Kisunla, has ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Eli Lilly's financial outlook is favorable, despite its $26.35 billion total debt. TTM net income was $6.14 billion, and it is expected to rise further as Zepbound's capacity catches up with demand.

Experimental Eli Lilly Alzheimer’s drug donanemab is being readied for an FDA submission along the same regulatory path the agency used to approve Biogen’s Aduhelm. Though the Lilly drug met ...

Bloomberg Intelligence projected that both donanemab and Eli Lilly’s remternetug, in Phase 3 trials, could dominate the Alzheimer’s market and lead to $6.5 billion in revenue by 2030.

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Eli Lilly (LLY-4.22%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).